{
  "id": 2085306,
  "title": "Mendus narrows Q2 loss as blood cancer trials advance",
  "url": "https://urgent.news/2026/08/20/mendus-narrows-q2-loss-as-blood-cancer-trials-advance",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-20T06:12:28.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/mendus-narrows-q2-loss-as-blood-cancer-trials-advance-93CH-4868733"
  },
  "original_language": "en",
  "account": "Swedish pharmaceutical firm Mendus narrowed its net loss for Q2 2026 compared to the same period last year, thanks to advancements in clinical trials for its blood cancer treatment, vididencel. The company reported a net loss of SEK 21.38 million, with an adjusted loss per share of SEK 0.34, and generated no revenue during the quarter. Operating loss stood at SEK 20.50 million. Progress was made on vididencel trials for acute myeloid leukemia and chronic myeloid leukemia, with enrollment milestones reached and regulatory approvals obtained. The company also entered a collaboration with South Australian Health and Medical Research Institute to prepare for a new chronic myeloid leukemia trial. Mendus formed a Clinical Advisory Board of international experts to support its clinical development. The company anticipates receiving initial results from its VITAL-CML trial in the second half of 2026 and expects to begin the VITAL-TFR2 trial in chronic myeloid leukemia during the same period. Additional clinical advances for vididencel in myeloid blood cancers are expected throughout 2026.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}